CEL-SCI Corporation (NYSE MKT: CVM) today announced that Turkey's Ministry
of Health has cleared the company to begin patient enrollment in CEL-SCI's
global pivotal Phase III Head and Neck Cancer clinical trial of its
investigational cancer immunotherapy treatment Multikine* (Leukocyte
Interleukin, Injection). The Company expects to enroll patients through
three clinical centers in Turkey. Turkey thus becomes the 16(th) country to
participate in the world's largest Phase III head and neck cancer trial.
"As we add more countries and subsequently more clinical centers, we see an
acceleration of the pace of the Phase III trial. In the most recently
reported three month period, we saw a 93% increase in patient enrollment
over the prior three month period," stated CEL-SCI Chief Executive Officer
Geert Kersten. "We are pleased with the progress of our clinical program as
we investigate the efficacy of Multikine immunotherapy to treat cancer."
Head and neck cancer accounts for about 6% of all cancers, with
approximately 600,000 new cases reported annually worldwide. CEL-SCI has
received U.S. Orphan Drug designation for Multikine in head and neck cancer
in the US.
Further expansion of the Phase III trial is underway with a goal to have a
total of 880 patients enrolled through about 100 clinical centers by the end
of 2015. Over 220 patients have been enrolled in the study to date.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in